Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view.

- **Fusion Proteins Specific**
  - BRD Amplifications Specific
  - MYC Amplifications Specific
  - AR Amplifications Specific

- **Tumor Mutation Burden**
  - High

- **Folate Receptor Alpha Expression**
  - TNBC, NSCLC, EC, OC

- **IRB# 18788**
  - Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

- **IRB# 18164**
  - A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

- **IRB# 16702**
  - A Phase I/IIa Trial With BMS-986158 as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors

- **IRB# 16676**
  - BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors

- **IRB# 17674**
  - Loxo-195 in fusion-NTRK (previously treated) solid tumors

- **IRB# 21548**
  - A Phase 1 Study of AMG 650 in Subjects With Advanced Solid Tumors

- **IRB# 21819**
  - A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors

- **IRB# 21349**
  - A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

- **6/10/2021**

http://www.ohsu.edu/research/rda/so/knight.php